ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?

被引：1
|
作者：
Ushida, Yuta [1 ]
Inoue, Yosuke [1 ]
Oba, Atsushi [1 ]
Mie, Takafumi [1 ]
Ito, Hiromichi [1 ]
Ono, Yoshihiro [1 ]
Sato, Takafumi [1 ]
Ozaka, Masato [1 ]
Sasaki, Takashi [1 ]
Saiura, Akio [1 ,2 ]
Sasahira, Naoki [1 ]
Takahashi, Yu [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Surg, Tokyo, Japan
[2] Juntendo Univ Hosp, Dept Hepatobiliary Pancreat Surg, Tokyo, Japan
来源：
ANNALS OF SURGICAL ONCOLOGY | 2022年 / 29卷 / 08期
关键词：
D O I：
10.1245/s10434-022-11621-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5051 / 5052
页数：2
相关论文
共 48 条
  • [1] ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
    Yuta Ushida
    Yosuke Inoue
    Atsushi Oba
    Takafumi Mie
    Hiromichi Ito
    Yoshihiro Ono
    Takafumi Sato
    Masato Ozaka
    Takashi Sasaki
    Akio Saiura
    Naoki Sasahira
    Yu Takahashi
    Annals of Surgical Oncology, 2022, 29 : 5051 - 5052
  • [2] Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
    Ide, Yasushi
    Otsuka, Taiga
    Shimokawa, Mototsugu
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Fukahori, Masaru
    Makiyama, Akitaka
    Shinohara, Yudai
    Ueno, Shohei
    Taguchi, Hiroki
    Honda, Takuya
    Shibuki, Taro
    Nio, Kenta
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    ANTICANCER RESEARCH, 2023, 43 (04) : 1817 - 1826
  • [3] Clinical outcome of initially unresectable pancreatic cancer patients: Conversion surgery after modified FOLFIRINOX or gemcitabine nab-paclitaxel
    Ushida, Yuta
    Inoue, Yosuke
    Ito, Hiromichi
    Ono, Yoshihiro
    Sato, Takafumi
    Takahashi, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [4] ASO Visual Abstract: Optimizing the Indications for Conversion Surgery Based on an Analysis of 54 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study
    Ushida, Yuta
    Inoue, Yosuke
    Oba, Atsushi
    Mie, Takafumi
    Ito, Hiromichi
    Ono, Yoshihiro
    Sato, Takafumi
    Ozaka, Masato
    Sasaki, Takashi
    Saiura, Akio
    Sasahira, Naoki
    Takahashi, Yu
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (8) : 5053 - 5054
  • [5] ASO Visual Abstract: Optimizing the Indications for Conversion Surgery Based on an Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study
    Yuta Ushida
    Yosuke Inoue
    Atsushi Oba
    Takafumi Mie
    Hiromichi Ito
    Yoshihiro Ono
    Takafumi Sato
    Masato Ozaka
    Takashi Sasaki
    Akio Saiura
    Naoki Sasahira
    Yu Takahashi
    Annals of Surgical Oncology, 2022, 29 : 5053 - 5054
  • [6] Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1)
    Okano, Naohiro
    Kawai, Manabu
    Ueno, Makoto
    Yu, Xianjun
    Inoue, Yosuke
    Takahashi, Shinichiro
    Wang, Wenquan
    Takahashi, Hidenori
    Okamura, Yukiyasu
    Morinaga, Soichiro
    Matsumoto, Ippei
    Shimizu, Yasuhiro
    Yoshida, Kazuhiro
    Yamamoto, Tomohisa
    Ohtsuka, Masayuki
    Inokawa, Yoshikuni
    Nara, Satoshi
    Tamura, Jun
    Shinoda, Satoru
    Yamamoto, Kouji
    Yamaue, Hiroki
    Furuse, Junji
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2024, 31 (11) : 816 - 829
  • [7] Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study
    Ushida, Yuta
    Inoue, Yosuke
    Oba, Atsushi
    Mie, Takafumi
    Ito, Hiromichi
    Ono, Yoshihiro
    Sato, Takafumi
    Ozaka, Masato
    Sasaki, Takashi
    Saiura, Akio
    Sasahira, Naoki
    Takahashi, Yu
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (08) : 5038 - 5050
  • [8] Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study
    Yuta Ushida
    Yosuke Inoue
    Atsushi Oba
    Takafumi Mie
    Hiromichi Ito
    Yoshihiro Ono
    Takafumi Sato
    Masato Ozaka
    Takashi Sasaki
    Akio Saiura
    Naoki Sasahira
    Yu Takahashi
    Annals of Surgical Oncology, 2022, 29 : 5038 - 5050
  • [9] Correction to: ASO Visual Abstract: Optimizing the Indications for Conversion Surgery Based on an Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study
    Yuta Ushida
    Yosuke Inoue
    Atsushi Oba
    Takafumi Mie
    Hiromichi Ito
    Yoshihiro Ono
    Takafumi Sato
    Masato Ozaka
    Takashi Sasaki
    Akio Saiura
    Naoki Sasahira
    Yu Takahashi
    Annals of Surgical Oncology, 2022, 29 : 6047 - 6047
  • [10] Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report
    Okura, Ryosuke
    Takano, Shigetsugu
    Yokota, Tetsuo
    Yoshitomi, Hideyuki
    Kagawa, Shingo
    Furukawa, Katsunori
    Takayashiki, Tsukasa
    Kuboki, Satoshi
    Suzuki, Daisuke
    Sakai, Nozomu
    Nojima, Hiroyuki
    Mishima, Takashi
    Miyazaki, Masaru
    Ohtsuka, Masayuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (04) : 389 - 393
12345